Retroviral transduction of a T cell receptor specific for an Epstein–Barr virus-encoded peptide
RJ Orentas, SJ Roskopf, GP Nolan, MI Nishimura - Clinical immunology, 2001 - Elsevier
The Type II EBV malignancies nasopharyngeal carcinoma and EBV+ Hodgkin's disease
express three subdominant antigens, latency membrane protein (LMP) 1, LMP2, and EBNA-
1. While adoptive immunotherapy with T cell lines for Type III EBV malignancy (such as
posttransplant lymphoma, PTLD, which expresses the immunodominant EBNA-3 antigens)
has been used to prevent and treat PTLD, the generation of class I MHC-restricted CTL
suitable for the immunotherapy of Type II EBV malignancy is difficult. This is primarily due to …
express three subdominant antigens, latency membrane protein (LMP) 1, LMP2, and EBNA-
1. While adoptive immunotherapy with T cell lines for Type III EBV malignancy (such as
posttransplant lymphoma, PTLD, which expresses the immunodominant EBNA-3 antigens)
has been used to prevent and treat PTLD, the generation of class I MHC-restricted CTL
suitable for the immunotherapy of Type II EBV malignancy is difficult. This is primarily due to …